Update: Rexahn Pharmaceuticals to Present at Nasdaq Marketsite

      Media and Investors Invited to the MarketSite, Times Square

  Tuesday, April 13, 2010, 12:15pm EDT, Others Invited to Video Webcast

ROCKVILLE, Md., April 12, 2010 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that Dr. Chang Ahn, Rexahn's Chief Executive Officer, will present at the NASDAQ MarketSite in Times Square, New York City.

Dr. Ahn will discuss Rexhan's important corporate developments in conjunction with a simultaneously issued press release.

When: April 13, 2010, 12:15 pm EDT

Where: NASDAQ MarketSite, 4 Times Square, New York, NY

Investors and media are welcome to attend: RSVP required for building security: 212 699-0999 or [email protected]

Video Webcast: Click here to schedule the LIVE WEBCAST LINK into your Outlook calendar. Select "open" then "save and close" when prompted. Click here to watch the event 4/13, 12:15pm

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin(R), Serdaxin(R), and Zoraxel(TM) - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.

Safe Harbor

This press release contains forward-looking statements. Rexahn's actual results may differ materially from anticipated results, and expectations expressed in these forward-looking statements, as a result of certain risks and uncertainties, including Rexahn's lack of profitability, and the need for additional capital to operate its business to develop its product candidates; the risk that Rexahn's development efforts relating to its product candidates may not be successful; the possibility of being unable to obtain regulatory approval of Rexahn's product candidates; the risk that the results of clinical trials may not be completed on time or support Rexahn's claims; demand for and market acceptance of Rexahn's drug candidates; Rexahn's reliance on third party researchers and manufacturers to develop its product candidates; Rexahn's ability to develop and obtain protection of its intellectual property; and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission. Rexahn assumes no obligation to update these forward-looking statements.

http://bhsmith.typepad.com/EVENTS/REXAHN%20PHARMACEUTICALS%20Media%20and%20Investor%20Conference.ics

CONTACT:  Stern Investor Relations, Inc.
          Investor Relations
          Stephanie Ascher
          212-362-1200
          [email protected]

          Base Pair Communications
          Constantine Theodoropulos
          617-401-3116
          [email protected]

Released April 12, 2010